AVA6000 approved by MHRA. Superb news. First dosing 'around mid-year'; first data to come within 3-4 months after that.

A summary thread on the significance of AVA6000 - and #AVCT's pre CISION platform as a whole - to both the oncology industry and to AVCT itself. 1/10

In very basic terms, #AVCT's pre CISION chemotherapies are essentially reformulated versions of existing, approved chemotherapies that have been used on cancer patients for many years - decades, even.

The pre CISION tech is simply an attempt to improve the safety profile... 2/10
...of the chemo.

Most therapeutics going through clinical trials look for an improvement of at least 20% over the existing industry-standard drug. A 50% increase in efficacy would usually be considered an astonishing result.

In pre-clinical mouse models for #AVCT's AVA6000 3/10
...18 times more pro-doxorubicin was found in the tumour than in the heart. Compare that to the 1:1 ratio of the standard doxorubicin.

What this means is that the pre CISION tech could be used to enable the giving of doses to patients that are multiple times more potent... 4/10
...than standard chemotherapy drugs - either in the form of greater number of cycles of chemo, or in the potency of the individual dose.

For example, in #AVCT's pre-clinical trials, pro-dox (AVA6000) doses were 6x more potent than the standard dox doses.

The results? The...5/10
...survival rate after 60 days for the standard-dox group was 0%; and 100% for the pro-dox group.

#AVCT isn't looking to improve chemotherapies by 25-30%, like most drugs in clinical trials.

Its pre CISION has the potential to improve the safety profile - and thus the... 6/10
...efficacy (via increased dosing) - by MULTIPLES. It is not an exaggeration to state that pre CISION could transform the chemo market - in fact, the overall oncology space. Survival rates could increase materially - as the mouse trials demonstrated. 7/10

https://t.co/XOEE45CBtZ
For #AVCT, it stands to reason that if the pro-dox trial is a success, then the pre CISION tech is also highly likely to work for other existing chemotherapies. @avacta has a pipeline of at least a dozen others in development.

AVCT holds the global exclusive licence over...8/10
...the pre CISION tech. It is also combining the tech with its second platform, Affimers - to create a third therapeutic platform, named TMAC.

TMAC will produce Affimer Drug Conjugates - a potentially more powerful class of oncology treatment than Antibody Drug Conjugates. 9/10
More on TMAC and AfDCs another time, but suffice to say that if they do work in man, #AVCT could become one of the most sought after oncology companies, globally.

First though, success for AVA6000 please!

Then hopefully @avacta's first TMAC drug to enter Phase I next year 10/10

More from Society

You May Also Like

A brief analysis and comparison of the CSS for Twitter's PWA vs Twitter's legacy desktop website. The difference is dramatic and I'll touch on some reasons why.

Legacy site *downloads* ~630 KB CSS per theme and writing direction.

6,769 rules
9,252 selectors
16.7k declarations
3,370 unique declarations
44 media queries
36 unique colors
50 unique background colors
46 unique font sizes
39 unique z-indices

https://t.co/qyl4Bt1i5x


PWA *incrementally generates* ~30 KB CSS that handles all themes and writing directions.

735 rules
740 selectors
757 declarations
730 unique declarations
0 media queries
11 unique colors
32 unique background colors
15 unique font sizes
7 unique z-indices

https://t.co/w7oNG5KUkJ


The legacy site's CSS is what happens when hundreds of people directly write CSS over many years. Specificity wars, redundancy, a house of cards that can't be fixed. The result is extremely inefficient and error-prone styling that punishes users and developers.

The PWA's CSS is generated on-demand by a JS framework that manages styles and outputs "atomic CSS". The framework can enforce strict constraints and perform optimisations, which is why the CSS is so much smaller and safer. Style conflicts and unbounded CSS growth are avoided.
Хајде да направимо мали осврт на случај Мика Алексић .

Алексић је жртва енглеске освете преко Оливере Иванчић .
Мика је одбио да снима филм о блаћењу Срба и мењању историје Срба , иза целокупног пројекта стоји дипломатски кор Британаца у Београду и Оливера Иванчић


Оливера Илинчић је иначе мајка једне од његових ученица .
Која је претила да ће се осветити .

Мика се налази у притвору због наводних оптужби глумице Милене Радуловић да ју је наводно силовао човек од 70 година , са три бајпаса и извађеном простатом пре пет година

Иста персона је и обезбедила финансије за филм преко Беча а филм је требао да се бави животом Десанке Максимовић .
А сетите се и ко је иницирао да се Десанка Максимовић избаци из уџбеника и школства у Србији .

И тако уместо романсиране верзије Десанке Максимовић утицај Британаца

У Србији стави на пиједестал и да се Британци у Србији позитивно афирмишу како би се на тај начин усмерила будућност али и мењао ток историје .
Зато Мика са гнушањем и поносно одбија да снима такав филм тада и почиње хајка и претње која потиче из британских дипломатских кругова

Најгоре од свега што је то Мика Алексић изговорио у присуству високих дипломатских представника , а одговор је био да се све неће на томе завршити и да ће га то скупо коштати .
Нашта им је Мика рекао да је он свој живот проживео и да могу да му раде шта хоће и силно их извређао